Ribbon Biolabs Raises EUR 18 Million Series A Financing Enabling Commercial Scale Production Facilities and US Expansion for DNA Synthesis Technology
VIENNA, AUSTRIA, January 31, 2022 —
Ribbon Biolabs, the DNA synthesis company, today
announced the successful close of EUR 18 million in its Series A funding round from a
consortium of European and US investors led by Hadean Ventures and with participation from
Lansdowne Partners, Helicase Venture as well as several undisclosed investors. Existing
investors IST cube and tecnet equity also joined in the round.
The funds will be used for the commercialization of Ribbon Biolabs’ DNA synthesis technology, which
uses an innovative approach integrating combinatorial optimization algorithms to guide the automated
enzymatic assembly of DNA. This includes the setup of production facilities with key technology
partners and the preparation for expansion into the US market. The investment will also support
Ribbon Biolabs’ ambitious recruitment plans as it continues to grow its team including key operational
and scientific positions located at the company’s facilities in Vienna and in the IST Park, the technology
park of the prestigious Institute of Science and Technology – IST Austria.
“We are more than excited and proud about this close as this fundraising enables us to expand our
production capabilities and collaborate with key partners,” commented Harold P. de Vladar, CEO and
founder of Ribbon Biolabs. “I value the financial commitment from both our existing investors and new
life science specialists as we grow our company and empower a new era of synthetic DNA
production.”
Ribbon Biolabs was founded in 2018 to redefine the potential of synthetic DNA. The technology
addresses the growing market need for synthetic DNA of sub-genomic size, an essential component
for developments in biopharmaceutical research and key for the disruptive potential of synthetic
biology. The company recently validated its capabilities by providing a synthetic DNA molecule of
10,000 base pairs (bp) in May 2021. In December 2021, the company extended this success by
synthesizing a 20,000 bp molecule.
Walter Stockinger, Managing Partner at Hadean Ventures added: “Synthetic biology is about to disrupt
the biopharmaceutical and other life science industries by overcoming previous limitations with new
genetic technologies. We are excited to support Ribbon Biolabs in its mission to fully automate long
DNA synthesis through its novel and proprietary approach and to become an important player in this
new field of biology.”
About Ribbon Biolabs
Ribbon Biolabs is a synthetic biology company advancing a new technology for the automated
synthesis of long DNA molecules to enable innovation in the life sciences. With its proprietary
technology in place, Ribbon Biolabs aims to be an inflection point in the continuing growth of the BioEconomy by becoming the leading partner for long DNA molecules.
About the investors
Hadean Ventures: https://hadeanventures.com
Helicase Venture: https://www.helicaseventure.com
IST Cube: https://ist-cube.com
Lansdowne Partners Austria: https://www.lansdownepartners.com/austria
tecnet equity: https://www.tecnet.at/en/
CONTACTS:
Ribbon Biolabs
Gabriele Schaller
[email protected]
Trophic Communications
Gretchen Schweitzer or Rachael Feord
+49 89 238 877-35 or +49 151 21941277
[email protected]